LANTHANUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lanthanum, and when can generic versions of Lanthanum launch?
Lanthanum is a drug marketed by Alkem Labs Ltd, Barr, Invagen Pharms, and Natco Pharma Ltd. and is included in four NDAs.
The generic ingredient in LANTHANUM is lanthanum carbonate. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the lanthanum carbonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lanthanum
A generic version of LANTHANUM was approved as lanthanum carbonate by NATCO PHARMA LTD on August 11th, 2017.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LANTHANUM?
- What are the global sales for LANTHANUM?
- What is Average Wholesale Price for LANTHANUM?
Summary for LANTHANUM
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 4 |
| Drug Prices: | Drug price information for LANTHANUM |
| DailyMed Link: | LANTHANUM at DailyMed |
US Patents and Regulatory Information for LANTHANUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Labs Ltd | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 202329-003 | Mar 13, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Invagen Pharms | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 206868-003 | Jan 24, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Barr | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 090977-003 | Jan 27, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
